Drug Information

Drug General Information
Drug ID
D0M9FQ
Former ID
DNCL001869
Drug Name
PF-489791
Drug Type
Small molecular drug
Indication Chronic obstructive pulmonary disease; Raynaud's disease [ICD9: 490-492, 494-496, 443; ICD10:J40-J44, J47, I73.0] Phase 2 [548422]
Company
Pfizer New York, NY
Formula
C20H28N8O4S
Canonical SMILES
CCN(C)C1=NC2=C(C(=N1)NC3=NC=CC(=C3)C)N(N=C2C(=O)NS(=O)(<br />=O)C)CCOCC
InChI
1S/C20H28N8O4S/c1-6-27(4)20-23-15-16(19(29)26-33(5,30)31)25-28(10-11-32-7-2)17(15)18(24-20)22-14-12-13(3)8-9-21-14/h8-9,12H,6-7,10-11H2,1-5H3,(H,26,29)(H,21,22,23,24)
InChIKey
ZUHZNKJIJDAJFD-UHFFFAOYSA-N
PubChem Compound ID
11465695
PubChem Substance ID
16565658, 23603862, 42544650, 77413944, 99431620, 137053217, 137741758, 141717853, 141717854, 141893115, 141893116, 172113516, 198990122, 226667864, 233588308, 247447988, 252166589
Target and Pathway
Target(s) CGMP-specific 3',5'-cyclic phosphodiesterase Target Info Inhibitor [551982]
KEGG Pathway Purine metabolism
cGMP-PKG signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Reactome cGMP effects
References
Ref 548422Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025495)
Ref 551982Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.